Mood disorders with hypomanic (not manic) episodes; bipolar II has full depressive episodes, cyclothymia has chronic subthreshold oscillation.
Also known as: bipolar II, BPII, cyclothymia, cyclothymic disorder
Overview
Bipolar II disorder (DSM-5-TR): ≥1 hypomanic episode (≥4 days, distinct change, ≥3 symptoms or 4 if irritable-only) PLUS ≥1 major depressive episode, and no history of a full manic episode. Cyclothymic disorder: ≥2 years (≥1 year in youth) of numerous periods with hypomanic symptoms and depressive symptoms that do NOT meet full episode criteria, present at least half the time and never symptom-free >2 months.
Epidemiology
Bipolar II 12-month prevalence ~0.3-0.8%; lifetime ~1.1%. Cyclothymia lifetime ~0.4-1%. Both have onset typically in adolescence to mid-20s. Bipolar II often misdiagnosed as MDD for years; mean delay to correct diagnosis ~10 years.
Try two board-style Bipolar II Disorder and Cyclothymic Disorder questions
Real questions from the FirstPassPA bank, with the full explanation. Pick an answer — no signup, no email.
Question 1PsychiatryMedium
A 30-year-old female has a history of recurrent depressive episodes and a single episode of decreased need for sleep, increased goal-directed activity, and elevated mood lasting 5 days that did not require hospitalization. Which of the following is the most likely diagnosis?
AMajor depressive disorder, recurrent
BCyclothymic disorder
CBipolar II disorder
DMajor depressive disorder with mixed features
EBipolar I disorder
Reveal answer & full explanation
Correct answer: C — Bipolar II disorder
AMajor depressive disorder, recurrent
BCyclothymic disorder
CBipolar II disorder✓
DMajor depressive disorder with mixed features
EBipolar I disorder
Why bipolar II disorder is correct
Bipolar II disorder requires at least one major depressive episode plus at least one hypomanic episode
Hypomania is defined as lasting >=4 days, being less severe than mania, occurring without psychosis or hospitalization, and being observable to others
This patient's episode (decreased need for sleep, increased goal-directed activity, elevated mood for 5 days, no hospitalization) meets hypomanic — not manic — criteria
Why the others are wrong
Bipolar I disorder — Bipolar I requires at least one manic episode (>=7 days, OR requiring hospitalization, OR with psychotic features); this patient's elevated-mood episode was 5 days with no hospitalization or psychosis
Cyclothymic disorder — Cyclothymic disorder requires 2+ years of hypomanic and depressive symptoms that do not meet full criteria for hypomanic or major depressive episodes
Major depressive disorder with mixed features — Major depressive disorder (MDD) with mixed features describes a depressive episode with some manic-like features, which does not account for a distinct hypomanic episode
Major depressive disorder, recurrent — recurrent MDD is a common misdiagnosis in bipolar II because patients usually seek care while depressed and hypomania goes unrecognized, but a lifetime hypomanic episode not attributable to a substance or another medical condition, such as this 5-day episode, excludes MDD and, together with her major depressive episodes and no history of mania, establishes bipolar II
Additional high-yield points
Treatment options include mood stabilizers: lithium, lamotrigine (particularly for bipolar II (BPII) depression), valproate, and atypical antipsychotics
Question 2PsychiatryMedium
A 26-year-old woman presents with 5 weeks of depressed mood, anhedonia, hypersomnia, and poor concentration. She has no suicidal ideation. On collateral interview, her partner describes a distinct 5-day period last year when she needed only 3 hours of sleep, spoke rapidly, started several projects, and made impulsive purchases; she was never hospitalized and had no psychotic symptoms. TSH and urine toxicology are normal, and beta-hCG is negative. Which of the following is the most appropriate initial management?
AVenlafaxine
BSertraline
CValproate
DAripiprazole
EQuetiapine
Reveal answer & full explanation
Correct answer: E — Quetiapine
AVenlafaxine
BSertraline
CValproate
DAripiprazole
EQuetiapine✓
Why Quetiapine is correct
The collateral history of a distinct >=4-day hypomanic episode (decreased need for sleep, pressured speech, increased goal-directed activity, impulsivity) plus a current major depressive episode, with no full mania or psychosis, establishes bipolar II disorder.
For an acute bipolar II depressive episode, quetiapine monotherapy has the strongest evidence and is the only first-line agent in the CANMAT/ISBD guidelines; lumateperone is also FDA-approved for bipolar II depression, whereas lurasidone and cariprazine are approved only for bipolar I depression.
Why the others are wrong
Sertraline — an SSRI; antidepressant monotherapy in bipolar disorder risks inducing hypomania, rapid cycling, or mixed states, so it is avoided in bipolar I disorder; for bipolar II depression CANMAT/ISBD 2018 ranks sertraline monotherapy second-line, behind quetiapine.
Venlafaxine — an SNRI; CANMAT/ISBD 2018 ranks venlafaxine monotherapy second-line for bipolar II depression, behind quetiapine, and it carries a higher mood-switch risk than SSRIs in bipolar depression.
Aripiprazole — an atypical antipsychotic, but unlike quetiapine it failed to separate from placebo in acute bipolar depression trials; its bipolar indications are acute mania/mixed episodes and maintenance, not a depressive episode.
Valproate — a classic mood stabilizer, which makes it tempting for any patient with bipolar disorder, but its evidence is strongest for acute mania and its data in bipolar II depression are limited; it is also a major teratogen that should generally be avoided in women of reproductive potential like this 26-year-old, even with a negative beta-hCG.
That's 2. Get 7,700+ more.
Unlock the full FirstPassPA bank: 7,700+ board-style questions, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
You've read your 2 free diagnosis previews. Create your free account to unlock the full Bipolar II Disorder and Cyclothymic Disorder outline — plus all 514 diagnoses, 7,700+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
First-degree relative with bipolar disorder (heritability ~70-80%)
Early onset of depressive symptoms (<25 yo)
Postpartum mood episode
Antidepressant-induced hypomania or rapid cycling
Comorbid substance use, ADHD, anxiety disorders
Pathophysiology
Heritable disturbance of mood regulation involving monoaminergic systems, circadian dysregulation, calcium-channel signaling (CACNA1C), and reduced prefrontal inhibition of limbic structures. Sleep deprivation and antidepressants can precipitate hypomania.
Clinical presentation
Symptoms
Hypomania: elevated/expansive or irritable mood, decreased need for sleep, increased energy and goal-directed activity, talkativeness, racing thoughts, distractibility, increased risk-taking — observable by others but NOT causing marked impairment or requiring hospitalization, and no psychosis
Depression: identical to MDD criteria — sad mood, anhedonia, sleep/appetite change, fatigue, guilt, concentration impairment, suicidal ideation
Cyclothymia: rapid shifts between subthreshold up and down periods, often described as 'moody' lifelong
Signs / physical exam
During hypomania: pressured speech, increased motor activity, intense engagement, may appear unusually productive
During depression: psychomotor retardation, low affect
Between episodes: often euthymic and high-functioning (BPII) or chronically unstable (cyclothymia)
Classic findings
Patient presents with depression and reports past 'best week of my life' periods of needing only 3 hours of sleep, completing massive projects, and spending impulsively — without ever being hospitalized or psychotic.
Differential diagnosis
Bipolar I disorder — Requires ≥1 full manic episode (≥7 days, marked impairment, psychosis, or hospitalization) — by definition absent in BPII
Major depressive disorder — No history of hypomania; carefully screen with MDQ or collateral — antidepressant monotherapy in undiagnosed BPII risks induction of hypomania
Borderline personality disorder — Mood lability over hours, identity disturbance, fear of abandonment, chronic emptiness — not discrete ≥4-day episodes
ADHD — Chronic, not episodic; distractibility and impulsivity without elevated mood or decreased need for sleep
Substance-induced mood disorder — Stimulants, cocaine, glucocorticoids — temporal link to use; resolves with sustained abstinence
Cyclothymic disorder — Chronic subthreshold oscillation never meeting full hypomanic or MDD criteria
Diagnostic workup
Diagnostic criteria
Bipolar II: ≥1 hypomanic episode (≥4 days, ≥3 of 7 symptoms, observable change, no marked impairment/psychosis/hospitalization) + ≥1 MDE; never met manic criteria. Cyclothymia: ≥2 yr (≥1 yr youth) of subthreshold hypomanic AND depressive symptoms, ≥half the time, no symptom-free interval >2 mo, criteria for an MDE, manic, or hypomanic episode have never been met.
Labs
TSH, CMP, CBC, vitamin B12, vitamin D
Urine toxicology screen (stimulants, cocaine)
HCG in women of reproductive age before mood stabilizers
Lithium baseline: BUN/Cr, TSH, calcium, ECG (if age >40 or cardiac risk)
Valproate baseline: LFTs, CBC, HCG
Imaging
Not routinely indicated
Neuroimaging if first episode late-life or focal neurologic findings
Diagnostic algorithm
flowchart TD
A[Mood symptoms] --> B{Ever a manic episode<br/>≥7 d / hospitalization /<br/>psychosis?}
B -->|Yes| C[Bipolar I disorder]
B -->|No| D{Discrete hypomanic<br/>episode ≥4 d?}
D -->|Yes| E{Ever had a full<br/>major depressive episode?}
E -->|Yes| F[Bipolar II Disorder]
E -->|No| G[Other specified<br/>bipolar disorder]
D -->|No| H{Chronic ≥2 yr<br/>subthreshold up/down?}
H -->|Yes| I[Cyclothymic Disorder]
H -->|No| J[Unipolar MDD<br/>or other dx]
F --> K[Mood stabilizer<br/>± atypical antipsychotic]
I --> K
Diagnostic algorithm distinguishing bipolar I, bipolar II, cyclothymia, and unipolar depression.
Treatment
First-line
Bipolar II acute depression: quetiapine (best evidence; the only CANMAT first-line agent); lumateperone is also FDA-approved for bipolar II depression (CANMAT second-line), while lurasidone and cariprazine are approved only for bipolar I depression
Bipolar II maintenance: lithium (anti-suicide benefit), lamotrigine (especially if depression-predominant), or quetiapine
Psychotherapy: CBT, family-focused therapy, interpersonal and social rhythm therapy (IPSRT)
Second-line / adjunct
Lithium or lamotrigine for acute bipolar II depression (CANMAT second-line); olanzapine-fluoxetine combination is approved only for bipolar I depression (weight/metabolic burden)
Adjunctive antidepressant only with concurrent mood stabilizer AND only if hypomania risk acceptable — avoid monotherapy
ECT for severe, refractory, or pregnant patients
Thyroid augmentation for refractory cycling
Complications
Conversion to bipolar I (~5-15% over time)
Suicide — risk in bipolar II is comparable to (not lower than) bipolar I, driven by the depression-predominant course
Substance use disorders (lifetime ~40%)
Occupational, financial, and relational damage during hypomania
Lithium: renal, thyroid, parathyroid effects with long-term use
Lamotrigine requires 6-week titration to reduce SJS risk — never load.
Lithium reduces suicide risk independent of mood effect — strongly consider in any bipolar patient with prior attempts.
Cyclothymia converts to bipolar I or II in 15-50% of patients over decades.
Always check beta-hCG and counsel on contraception before valproate (NTD risk) or carbamazepine.
References
DSM-5-TR — American Psychiatric Association. DSM-5-TR. 2022.
CANMAT 2018 — Yatham LN et al. CANMAT and ISBD 2018 Guidelines for the Management of Patients with Bipolar Disorder. Bipolar Disord 2018;20(2):97-170.
CANMAT/ISBD 2023 update — Keramatian K, Chithra NK, Yatham LN. The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus (Am Psychiatr Publ) 2023;21(4):344-353.
Practice Psychiatry/Behavioral questions on FirstPassPA
Turn this outline into retention. 7,700+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Educational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.